A Study to Evaluate Nivolumab in the Treatment of Early Stage Esophageal or Gastroesophageal Cancer

TerminatedOBSERVATIONAL
Enrollment

33

Participants

Timeline

Start Date

August 4, 2023

Primary Completion Date

August 23, 2024

Study Completion Date

August 23, 2024

Conditions
Esophageal CarcinomaGastroesophageal Junction Carcinoma
Trial Locations (24)

1307

BAG Freiberg-Richter, Jacobash, Illmer, Wolf, Dresden

9113

Klinikum Chemnitz Ggmbh, Chemnitz

30169

Onkologische Schwerpunktpraxis Dres. Ingo Zander und Eyck von der Heyde, Hanover

34125

Klinikum Kassel, Kassel

39120

Universitätsklinik Magdeburg, Magdeburg

40202

University Of Louisville, Louisville

45136

Alexianer, Maria-Hilf-Krankenhaus, Essen

45657

Oncologianova GmbH, Recklinghausen

53127

Universitätsklinikum Bonn, Bonn

55131

Local Institution - 0006, Mainz

66113

CaritasKlinikum Saarbruecken., Saarbrücken

66424

Local Institution - 0033, Homburg

72076

Universitätsklinikum Tübingen, Tübingen

81925

Klinikum Munchen-Bogenhausen, München

35233-1711

University of Alabama at Birmingham, Birmingham

93401-7970

Pacific Central Coast Health Centers - San Luis Obispo Oncology and Hematology Health Center, San Luis Obispo

93454-5909

Mission Cancer Center, Santa Maria

83706-1309

Saint Alphonsus Regional Medical Center, Boise

66205-2005

UPMC Hillman Cancer Center, Westwood

10065-6007

Weill Cornell Medical College, New York

75390-7208

Local Institution - 0009, Dallas

79906-5327

William Beaumont Army Medical Center, Fort Bliss

77030-4000

The University Of Texas, Houston

76508-0001

Baylor Scott and White Health, Temple

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

PPD Development, LP

INDUSTRY

lead

Bristol-Myers Squibb

INDUSTRY